Hyperlipidemia
Episodes 17-32 of 36
Pam R. Taub, MD, FACC, FASPC
Erik Stroes, MD, PhD
P. Gabriel Steg, MD
Pam R. Taub, MD, FACC, FASPC
Erik Stroes, MD, PhD
- MinuteCE®
Novel oral pathways in LDL-C lowering therapy: The new promise of CETPi
1.00 program creditErin D. Michos, MD, MHS, FACC, FAHA, FASE
Kausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
Fabrice Martens, MD, PhD, FESC
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Fabrice Martens, MD, PhD, FESC
- MinuteCE®
The evolving need and challenges to reach LDL-c targets in high-risk patients
1.00 program creditKausik Ray, MBChB, MD, MPhil
Lale Tokgözoğlu, MD
- MinuteCE®
New insights on CETP inhibition from genetic research and clinical trials
1.00 program creditJohn Kastelein, MD, PhD
Roxana Mehran, MD
Stephen Nicholls, FRACP, FACC, FESC, FAHA
Stephen Nicholls, FRACP, FACC, FESC, FAHA
John Kastelein, MD, PhD
Roxana Mehran, MD
Lale Tokgözoğlu, MD
Richard Hobbs, MD
- MinuteCE®
Integrating icosapent ethyl in preventive strategies: Practical guidance
1.00 program creditVictor Aboyans, MD, PhD
- MinuteCE®
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
1.00 credit 3 episodesRichard Hobbs, MD
Lale Tokgözoğlu, MD
Victor Aboyans, MD, PhD
